Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis

Alemnew F. Dagnew, Osman Ilhan, Won Sik Lee, Dariusz Woszczyk, Jae Yong Kwak, Stella Bowcock, Sang Kyun Sohn, Gabriela Rodriguez Macías, Tzeon Jye Chiou, Dimas Quiel, Mickael Aoun, Maria Belen Navarro Matilla, Javier de la Serna, Samuel Milliken, John Murphy, Shelly A. McNeil, Bruno Salaun, Emmanuel Di Paolo, Laura Campora, Marta López-FauquedMohamed El Idrissi, Anne Schuind, Thomas C. Heineman, Peter Van den Steen, Lidia Oostvogels, Kadir Acar, Boris Afanasyev, Aránzazu Alonso Alonso, Veli Jukka Anttila, Pere Barba Suñol, Norbert Blesing, Terrance Comeau, Teresa del Campo, Patricia Disperati, Richard Eek, Hyeon Seok Eom, Gianluca Gaidano, Sebastian Grosicki, Thierry Guillaume, Wojciech Homenda, William Hwang, Nikolay Ilyin, Anna Johnston, Seok Jin Kim, Ching Yuan Kuo, Aleksey Kuvshinov, Dong Gun Lee, Jae Hoon Lee, Je Jung Lee, Stephane Lepretre, Albert Kwok Wai Lie, Alessandro Lucchesi, Ahmed Masood, Naheed Mir, Anna Carolina Miranda Castillo, Kathleen Mullane, Alexandr Myasnikov, Raquel Oña Navarrete, Karlis Pauksens, Andrew Peniket, Jaime Perez de Oteyza, David Pohlreich, Humphrey Pullon, Philippe Quittet, Philippe Rodon, Lars Rombo, Olga Samoylova, Johan Sanmartin Berglund, Ariah Schattner, Dominik Selleslag, Marjatta Sinisalo, Faisal Sultan, Koen Theunissen, Paul Turner, Po Nan Wang, Lucrecia Yáñez San Segundo, Jo Anne Young, Pierre Zachee, Francesco Zaja

Research output: Contribution to journalArticlepeer-review

47 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis'. Together they form a unique fingerprint.

Medicine & Life Sciences